Research
Dual GIP-GLP-1 RA shows superior efficacy in lowering POAG, OHT risk
Tirzepatide consistently reduced the risk of glaucomatous disease compared to GLP-1 RAs, even among high-risk patients.
Research
GLP-1 use may lower long-term DME, DR risk
Study highlights protective effect of GLP-1 RAs against ocular complications of diabetes and disparities for racialized patients
Research
AOA report analyzes ocular risks of GLP-1RAs
Released during the 2025 Optometry’s Meeting, this comprehensive rundown dives into potential rare ophthalmic side effects associated with use—and offers clinical care recommendations.
Research
GLP-1 drug users twice as likely to develop nAMD
New research findings also report risk was 3 times as high among diabetic patients with the longest exposure to GLP-1 RAs.Research
Could GLP-1 receptor agonists reduce AMD risk?
GLP-1 receptor agonists demonstrate a notable effect on the risk of non-exudative AMD.
Research
DME risk may decrease with use of GLP-1 agonists and fenofibrates
Diabetic patients taking calcium channel blockers demonstrated the opposite effect.
Research
How effective are GLP-1 agonists in protecting against glaucoma?
GLP-1 receptor agonist use linked with significantly decreased risk of developing glaucoma and ocular hypertension.
Research
AAO, NANOS respond to study on semaglutide-NAION connection
Recent research identified substantial risk for NAION development among diabetic and obese patients using the GLP-1 RA.
Research